Nutriband Inc (NTRB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nutriband Inc (NTRB) has a cash flow conversion efficiency ratio of -0.110x as of January 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-731.83K) by net assets ($6.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Nutriband Inc to measure how much of total assets are equity-financed.
Nutriband Inc - Cash Flow Conversion Efficiency Trend (2016–2026)
This chart illustrates how Nutriband Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow reinvestment rate of Nutriband Inc to assess the company's total reinvestment commitment from operating cash flow.
Nutriband Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nutriband Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Molecure S.A.
WAR:MOC
|
0.266x |
|
Konsortium Transnasional Bhd
KLSE:4847
|
-0.286x |
|
JNK Heaters Co. Ltd
KQ:126880
|
0.166x |
|
SJM Co Ltd
KO:123700
|
0.046x |
|
Lider Faktoring AS
IS:LIDFA
|
-0.140x |
|
Namibia Critical Metals Inc
V:NMI
|
0.002x |
|
IFCA MSC Bhd
KLSE:0023
|
-0.058x |
|
Samwha Elec
KO:011230
|
-0.072x |
Annual Cash Flow Conversion Efficiency for Nutriband Inc (2016–2026)
The table below shows the annual cash flow conversion efficiency of Nutriband Inc from 2016 to 2026. For the full company profile with market capitalisation and key ratios, see Nutriband Inc (NTRB) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-01-31 | $6.68 Million | $-5.13 Million | -0.769x | -6.81% |
| 2025-01-31 | $6.43 Million | $-4.63 Million | -0.720x | -31.36% |
| 2024-01-31 | $6.44 Million | $-3.53 Million | -0.548x | -57.24% |
| 2023-01-31 | $8.57 Million | $-2.99 Million | -0.348x | -47.10% |
| 2022-01-31 | $11.86 Million | $-2.81 Million | -0.237x | -467.13% |
| 2021-01-31 | $7.11 Million | $-297.06K | -0.042x | +99.18% |
| 2020-01-31 | $175.43K | $-894.47K | -5.099x | -1009.06% |
| 2019-01-31 | $2.40 Million | $-1.11 Million | -0.460x | +39.84% |
| 2018-01-31 | $121.51K | $-92.86K | -0.764x | +88.06% |
| 2017-01-31 | $23.11K | $-147.92K | -6.401x | -149.63% |
| 2016-01-31 | $-11.47K | $-147.92K | 12.897x | -- |
About Nutriband Inc
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA b… Read more